CAR T cells

Phase 3Cell therapy

CChongqing Precision Biotech Co., Ltd

CAR T cells is one of 215 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

214

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

MesotheliomaActive, not recruiting

HIV-1 InfectionActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Gastric CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Immune ThrombocytopeniaActive, not recruiting

LymphomaPhase 1

Active, not recruiting

MesotheliomaPhase 1

Active, not recruiting

HIV-1 InfectionPhase 1

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Gastric CancerPhase 3

Active, not recruiting

Multiple MyelomaPhase 1/Phase 2

Active, not recruiting

Immune ThrombocytopeniaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

CAR T cells

CChongqing Precision Biotech Co., Ltd

Phase 3

7 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Oncaspar

SServier

Preclinical

15 5

Zofran

Novartis

Preclinical

2 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Tafasitamab

Incyte

Preclinical

7 8

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 10

Nuvigil

NNuvo Research GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Lymphoma

NCT06822868

Phase 1Active, not recruiting

Mesothelioma

NCT04577326

Q4 2026

Phase 1Recruiting

Hematological Malignancies

NCT04532203

Phase 1Recruiting

Lymphoma

NCT07053670

Phase 1Not yet recruiting

Lymphoma

NCT07032324

Q2 2027

Phase 3Recruiting

Gastric Cancer

NCT07103668

Clinical

Trials by Indication[1]

Lymphoma7 trials

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Recruiting·KKai Hu·Phase 1·NCT06822868·24 enrolled

To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

Recruiting·NNational University of Malaysia·Phase 2·NCT06698484·20 enrolled

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

Active, not recruiting·BBenjamin Tomlinson·Phase 1·NCT03434769·31 enrolled

Show 4 more trials

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Unknown status·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT05420493·54 enrolled

A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma

Recruiting·AAibin Liang，MD，Ph.D.·Phase 1·NCT06734871·24 enrolled

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )

Recruiting·TTongji Hospital·Phase 1·NCT07053670·27 enrolled

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )

Not yet recruiting·QQian Wenbin·Phase 1·NCT07032324·27 enrolled

Hematological Malignancies3 trials

Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions

Unknown status·ZZhejiang University·Phase 1/2·NCT04790747·50 enrolled

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Recruiting·ZZhejiang University·Phase 1·NCT04532203·72 enrolled

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Available·IInstitute of Hematology & Blood Diseases Hospital, China··NCT04008524

T Cells2 trials

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 1·NCT05779917·30 enrolled

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Unknown status·TThe First Affiliated Hospital of Guangdong Pharmaceutical University·Phase 1/2·NCT03525782·60 enrolled

Multiple Myeloma2 trials

Multiple Antigen-specific CAR T Cells For the Treatment of Multiple Myeloma

Recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT03271632·20 enrolled

Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma With BCMA and GPRC5D Combination CAR-T Cell Therapy

Recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT06429150·20 enrolled

B-cell Malignancies1 trial

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Unknown status·HHenan Cancer Hospital·Phase 1·NCT03881774·20 enrolled

10 more indications

Advanced Solid Tumors1 trial

Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors

Unknown status·SShanghai Cell Therapy Group Co.,Ltd·Phase 1·NCT05089266·30 enrolled

HIV-1 infection1 trial

Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection

Unknown status·—·Phase 1·NCT04863066·8 enrolled

Mesothelioma1 trial

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04577326·14 enrolled

Refractory1 trial

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

Completed·UUppsala University·Phase 2·NCT03068416·24 enrolled

T Cell1 trial

Universal CAR-γδT Cell Injection in the AML Patients

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT05388305·30 enrolled

Treatment1 trial

Donor-derived CAR-T Cells in the Treatment of AML Patients

Unknown status·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1·NCT04766840·9 enrolled

Immune Thrombocytopenia1 trial

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

Recruiting·—·Phase 1/2·NCT06352281·10 enrolled

Acute Lymphoblastic Leukemia1 trial

Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia

Unknown status·—·Phase 1·NCT02186860·5 enrolled

Gastric Cancer1 trial

A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

Recruiting·SSuzhou Immunofoco Biotechnology Co., Ltd·Phase 3·NCT07103668·150 enrolled

Immune Function1 trial

The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function

Recruiting·GGuangzhou 8th People's Hospital·Phase 1·NCT03240328·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 25 trial records for CAR T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAR T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAR T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chongqing Precision Biotech Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: CChongqing Precision Biotech Co., Ltd

CAR T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Trials by Indication[1]

Lymphoma7 trials

Hematological Malignancies3 trials

T Cells2 trials

Multiple Myeloma2 trials

B-cell Malignancies1 trial

Advanced Solid Tumors1 trial

HIV-1 infection1 trial

Mesothelioma1 trial

Refractory1 trial

T Cell1 trial

Treatment1 trial

Immune Thrombocytopenia1 trial

Acute Lymphoblastic Leukemia1 trial

Gastric Cancer1 trial

Immune Function1 trial

References

Drug Info

Quick Facts

Related News